🔍

MANGALAM - Mangalam Drugs

📊 NSE: MANGALAM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 9:33

📢 Recent Corporate Announcements

Mangalam Drugs Appoints Jeevan M. Dalvi as CFO; Re-appoints Independent Director

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 06 Feb 2026, 03:03 PM

Mangalam Drugs and Organics Limited has announced key leadership changes, including the appointment of Mr. Jeevan M. Dalvi as the new Chief Financial Officer effective February 6, 2026. Mr. Dalvi brings over 20 years of experience in finance and accounts, specializing in cost-saving measures. Additionally, the board approved the re-appointment of Dr. Praveen Saxena as an Independent Director for a second five-year term starting March 2026. These updates follow the resignation of Independent Director Shri Rukmesh P. Dhandhania, who retired from professional responsibilities in January 2026.

Appointment of Mr. Jeevan M. Dalvi as CFO effective February 6, 2026, with 20+ years of experience.
Re-appointment of Dr. Praveen Saxena as Independent Director for a 5-year term until March 2031.
Resignation of Shri Rukmesh P. Dhandhania as Independent Director effective January 16, 2026.
New CFO expertise focuses on financial advisory, cost-saving, and process improvement.

💡 Investors should monitor the new CFO's impact on the company's financial processes and cost management. The re-appointment of an experienced director provides stability to the board's strategic oversight.

Mangalam Drugs Appoints Jeevan M. Dalvi as CFO; Re-appoints Independent Director

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 06 Feb 2026, 02:54 PM

Mangalam Drugs and Organics Limited has announced the appointment of Mr. Jeevan M. Dalvi as the Chief Financial Officer (CFO) effective February 6, 2026. Mr. Dalvi brings over 20 years of experience in accounts and finance, with expertise in cost-saving measures and financial process improvement. Additionally, the board approved the re-appointment of Dr. Praveen Saxena as an Independent Director for a second five-year term starting March 21, 2026. These changes follow the resignation of Independent Director Shri Rukmesh P. Dhandhania, who stepped down in January 2026 to retire from professional responsibilities.

Mr. Jeevan M. Dalvi appointed as Chief Financial Officer and Key Managerial Personnel effective February 6, 2026.
Mr. Dalvi has over 2 decades of experience in accounts, finance, and financial advisory.
Dr. Praveen Saxena re-appointed as Independent Director for a second term of 5 years (2026-2031).
Resignation of Independent Director Shri Rukmesh P. Dhandhania accepted effective January 16, 2026.
The board meeting concluded at 2:25 P.M. on February 6, 2026.

💡 Investors should monitor the transition in the finance department to see if the new CFO's expertise in cost-saving measures impacts the company's margins in upcoming quarters.

CRISIL Downgrades Mangalam Drugs to 'D' (Default) Rating on Rs 115 Cr Bank Facilities

🔴 NEGATIVE ⭐ 10/10

REGULATORY 📅 03 Feb 2026, 05:30 PM

CRISIL has downgraded Mangalam Drugs and Organics Limited's credit rating to 'CRISIL D' for its Rs 115 crore bank facilities, indicating the company is in default. The downgrade stems from the company overdrawing cash credit facilities for more than 30 days and defaulting on Covid loan payments. Additionally, the company has been tagged as 'Issuer Not Cooperating' due to its failure to provide necessary financial information and alleged misrepresentation of its debt-servicing ability in October 2025. Financial health has severely weakened, with the company reporting a net loss of Rs 13.73 crore for the quarter ending June 2025.

Ratings for Rs 115 crore bank facilities downgraded to 'CRISIL D' from 'CRISIL BB+/Stable'.
Company defaulted on Covid loans and overextended cash credit facilities for over 30 days.
Classified as 'Issuer Not Cooperating' after failing to respond to multiple CRISIL communications since October 2025.
Reported a significant net loss of Rs 13.73 crore and negative operating margins of -7.85% in June 2025.
CRISIL highlighted misrepresentation in the company's No Default Statement (NDS) regarding its ability to honor October 2025 obligations.

💡 Investors should exercise extreme caution as a 'D' rating signifies a default on debt obligations and high credit risk. The allegations of misrepresentation and lack of management cooperation are serious corporate governance red flags.

Mangalam Drugs Independent Director Rukmesh P. Dhandhania Resigns Effective Jan 16, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 17 Jan 2026, 04:24 PM

Shri Rukmesh P. Dhandhania has resigned from his position as a Non-Executive Independent Director of Mangalam Drugs and Organics Limited, effective January 16, 2026. He cited personal commitments and a desire to retire from professional responsibilities as the primary reasons for his departure. Following his resignation, he will also cease to be a member of the company's Audit Committee and the Nomination and Remuneration Committee. The company has confirmed that there are no other material reasons for this resignation beyond those stated.

Shri Rukmesh P. Dhandhania (DIN: 02493968) resigned as Independent Director effective close of business Jan 16, 2026.
The resignation leads to his exit from the Audit Committee and the Nomination and Remuneration Committee.
The director confirmed there are no material reasons for resignation other than personal commitments and retirement.
The outgoing director holds no other directorships in listed entities as per the disclosure.

💡 This is a routine board change and does not require any immediate action from investors. Monitor future filings for the appointment of a replacement to ensure the board remains compliant with SEBI regulations.

Mangalam Drugs Defaults on ₹15.56 Crore Bank Loan Payments to BoM and BoB

🔴 NEGATIVE ⭐ 9/10

REGULATORY 📅 16 Jan 2026, 03:56 PM

Mangalam Drugs and Organics Limited has reported a default on its loan obligations to Bank of Maharashtra and Bank of Baroda. The total overdue amount as of January 15, 2026, stands at ₹15.56 Crores across two cash credit accounts. The defaults began in mid-October 2025 and have persisted for over 30 days, triggering mandatory SEBI disclosure requirements. The company has stated it is making arrangements to settle the overdue amounts as soon as possible.

Total overdue amount of ₹1555.63 Lacs (₹15.56 Crores) across two major banks
Default of ₹1040.71 Lacs to Bank of Maharashtra starting from October 17, 2025
Default of ₹514.92 Lacs to Bank of Baroda starting from October 20, 2025
The defaults involve Cash Credit facilities where balances exceeded limits for over 30 days

💡 Investors should exercise extreme caution as persistent defaults indicate severe liquidity issues and potential credit rating downgrades. Monitor the company's ability to raise funds or restructure debt to clear these dues.

Mangalam Drugs CFO Ajay Samant and CS Anuradha Pandey Resign; Q3 Results Approved

🔴 NEGATIVE ⭐ 6/10

MANAGEMENT 📅 15 Jan 2026, 07:06 PM

Mangalam Drugs and Organics Limited has announced the resignation of its Chief Financial Officer, Mr. Ajay Avinash Samant, effective January 31, 2026, citing health reasons. Simultaneously, the Company Secretary and Compliance Officer, Ms. Anuradha Pandey, has also tendered her resignation. These leadership changes were approved during a board meeting on January 15, 2026, where the company also cleared its unaudited financial results for the quarter. Notably, the statutory auditors have issued an unmodified opinion on the financial statements, suggesting no immediate accounting concerns despite the management churn.

CFO Ajay Samant to step down effective January 31, 2026, following his resignation letter dated November 5, 2025.
Company Secretary Anuradha Pandey resigned on January 2, 2026, creating a dual vacancy in Key Managerial Personnel (KMP).
The Board approved unaudited standalone and consolidated financial results for the quarter ended January 15, 2026.
Statutory auditors expressed an unmodified opinion on the financial results, indicating no major audit qualifications.
The Board meeting concluded at 2:30 P.M. on January 15, 2026, after transacting these key management and financial items.

💡 Investors should monitor the company's upcoming appointments for the CFO and CS roles to ensure continuity in financial oversight and compliance. While the clean audit report is a positive sign, the simultaneous exit of two key officers warrants a cautious approach toward corporate governance.

Mangalam Drugs Reports Q3 Net Loss of ₹4.41 Cr; CFO and Company Secretary Resign

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 15 Jan 2026, 05:43 PM

Mangalam Drugs and Organics reported a poor financial performance for Q3 FY26, posting a consolidated net loss of ₹4.41 crore compared to a profit of ₹3.51 crore in the same period last year. Revenue from operations saw a sharp decline of 34% YoY, falling to ₹58.49 crore from ₹88.71 crore. Adding to the financial stress, the company announced the resignations of its Chief Financial Officer, Ajay Samant, and Company Secretary, Anuradha Pandey. For the nine-month period ending December 2025, the company has accumulated a total net loss of ₹16.73 crore.

Consolidated revenue from operations fell 34% YoY to ₹58.49 crore in Q3 FY26.
Reported a net loss of ₹4.41 crore for the quarter versus a profit of ₹3.51 crore in Q3 FY25.
Total expenses of ₹64.38 crore exceeded total income for the quarter, leading to operational losses.
CFO Ajay Samant resigned effective January 31, 2026, citing health reasons.
Company Secretary Anuradha Pandey resigned effective March 29, 2026, to pursue other opportunities.

💡 Investors should exercise caution as the company is facing both financial losses and a vacuum in key managerial positions. The significant YoY revenue drop and transition to a net loss suggest fundamental operational challenges.

Mangalam Drugs Reports Q3 Revenue Decline to ₹58.49 Cr; CFO and CS Resign

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 15 Jan 2026, 05:37 PM

Mangalam Drugs and Organics reported a significant decline in consolidated revenue for Q3 FY26, falling to ₹58.49 crore from ₹88.71 crore in the same quarter last year. The company faced an operational loss as total expenses of ₹64.38 crore exceeded its total income for the quarter. Adding to the financial pressure, the company announced the resignations of two Key Managerial Personnel: the Chief Financial Officer (CFO) and the Company Secretary. The 9-month performance also shows a sharp downward trend, with revenue dropping nearly 32% year-on-year.

Consolidated revenue for Q3 FY26 fell 34% YoY to ₹58.49 crore from ₹88.71 crore.
Total expenses for the quarter stood at ₹64.38 crore, leading to an operational loss before other income and tax.
9-month revenue for FY26 declined to ₹165.38 crore compared to ₹245.19 crore in the previous year period.
CFO Ajay Samant resigned effective January 31, 2026, citing health reasons.
Company Secretary Anuradha Pandey resigned effective March 29, 2026, to pursue other opportunities.

💡 Investors should exercise caution as the company is struggling with both declining top-line performance and the simultaneous exit of key leadership. It is advisable to wait for signs of operational stabilization and the appointment of new management before considering new positions.

Mangalam Drugs Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Jan 2026, 06:17 PM

Mangalam Drugs and Organics Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by MUFG Intime India Private Limited, covers the quarter ended December 31, 2025. It confirms that all share certificates received for dematerialization were processed, mutilated, and cancelled within the prescribed timelines. This is a standard administrative filing ensuring the company's share registry is maintained according to regulatory standards.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent, MUFG Intime India Private Limited
Confirms dematerialization requests were processed and securities listed on exchanges
Verification of mutilation and cancellation of physical certificates as per SEBI norms

💡 No action is required as this is a routine regulatory disclosure. Investors should continue to monitor the company's operational performance and upcoming financial results.

Mangalam Drugs Clarifies No Undisclosed Material Information Amid Stock Price Movement

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 07 Jan 2026, 12:11 PM

Mangalam Drugs and Organics Limited has responded to a surveillance inquiry from the National Stock Exchange regarding recent significant movements in its share price. The company stated that the price volatility is driven by market sentiments and is not related to any internal developments. They confirmed that all material information has been disclosed in a timely manner as per regulatory requirements. Currently, there is no pending price-sensitive information or announcement that needs to be disseminated to the market.

Responded to NSE surveillance letter Ref. No.: NSE/CM/Surveillance/16290 dated January 5, 2026
Company attributes recent stock price movement entirely to market sentiments of investors
Confirmed that no material information or price-sensitive announcements are currently pending
Reiterated commitment to disclosing all material information as per listing regulations

💡 Investors should view this as a routine regulatory clarification and focus on the company's financial performance rather than speculative price movements. No immediate portfolio action is required based on this disclosure.

Mangalam Drugs Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Jan 2026, 05:00 PM

Mangalam Drugs And Organics Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's quarterly financial reporting. The window will remain closed until 48 hours after the declaration of the un-audited financial results for the quarter ended December 31, 2025. This is a standard regulatory procedure and does not indicate any change in company fundamentals.

Trading window for designated persons closed effective from January 1, 2026.
Closure is related to the upcoming un-audited financial results for the quarter ended December 31, 2025.
The window will reopen 48 hours after the financial results are officially declared to the exchanges.
Compliance follows SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 No action is required as this is a routine regulatory filing. Investors should monitor the upcoming quarterly results for actual performance indicators.

Mangalam Drugs Defaults on ₹11.54 Crore Loan Payments to PSU Banks

🔴 NEGATIVE ⭐ 9/10

REGULATORY 📅 20 Dec 2025, 04:55 PM

Mangalam Drugs and Organics Limited has reported a subsequent default on its cash credit facilities with Bank of Baroda and Bank of Maharashtra. As of December 17, 2025, the total overdue amount stands at ₹1,153.76 Lacs. The default has persisted for more than 30 days, triggering mandatory disclosure under SEBI (LODR) Regulations. The company's management has stated that they are making arrangements to settle the overdue amounts as soon as possible.

Total overdue amount of ₹1,153.76 Lacs across two major public sector banks
Default of ₹707.05 Lacs to Bank of Maharashtra on cash credit account
Default of ₹446.71 Lacs to Bank of Baroda on cash credit account
Default duration has exceeded the 30-day threshold for revolving facilities
Management is currently arranging funds to clear the outstanding dues

💡 Investors should exercise extreme caution as loan defaults indicate severe liquidity stress and potential solvency issues. Monitor for any further credit rating downgrades or legal actions by the lending banks.

Mangalam Drugs Defaults on Rs 11.54 Crore Loan Payments to PSU Banks

🔴 NEGATIVE ⭐ 9/10

REGULATORY 📅 19 Dec 2025, 04:49 PM

Mangalam Drugs and Organics Limited has officially disclosed defaults on its cash credit facilities with Bank of Maharashtra and Bank of Baroda. The total overdue amount is approximately Rs 11.54 crore, which has remained unpaid for over 30 days. Specifically, the company owes Rs 7.07 crore to Bank of Maharashtra and Rs 4.47 crore to Bank of Baroda. Management has indicated that they are currently making arrangements to settle these overdue amounts as soon as possible.

Total default amount of Rs 11.54 crore reported across two bank accounts.
Rs 707.05 Lacs overdue to Bank of Maharashtra with default starting October 17, 2025.
Rs 446.77 Lacs overdue to Bank of Baroda with default starting October 20, 2025.
Defaults have persisted for more than 30 days, triggering mandatory SEBI disclosure requirements.
The company is currently seeking arrangements to clear the outstanding dues.

💡 Investors should exercise extreme caution as debt defaults are a major red flag indicating severe liquidity stress. Monitor for potential credit rating downgrades and the company's ability to clear these dues in the immediate term.

View All MANGALAM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue from operations decreased by 13.66% YoY, falling from INR 36,859.47 Lakhs in FY 2023-24 to INR 31,823.02 Lakhs in FY 2024-25. For the half-year ended September 30, 2025, the company reported a significant downturn with a net loss before tax of INR 2,546.50 Lakhs compared to a profit of INR 178.45 Lakhs in the same period of the previous year.

Geographic Revenue Split

Historical data indicates a heavy domestic focus with 83% of revenue derived from the Indian market as of FY16. Recent updates highlight a growing international presence through repeat export orders, such as a recent INR 15 Crore order for Anti-Malarial APIs from an international client.

Profitability Margins

Net Profit Margin improved to 0.02% in FY 2024-25 from a negative 0.02% in FY 2023-24. Operating Margin Ratio increased to 0.06% in FY 2024-25 from 0.01% in FY 2023-24. However, H1 FY26 shows severe margin pressure with a total comprehensive loss of INR 2,123.44 Lakhs.

EBITDA Margin

Historical EBITDA margins reached 12.8% in FY16. In FY 2024-25, the operating margin stood at 6%, but the company faced a sharp decline in H1 FY26, reporting an operating loss before working capital changes of INR 766.03 Lakhs.

Capital Expenditure

Not explicitly disclosed in absolute INR Cr for the current period; however, the company has a history of upgrading facilities, such as the Facility 1 upgrade in 2011 to support Anti-Retroviral API production.

Credit Rating & Borrowing

The Debt-Equity Ratio improved to 0.65 in FY 2024-25 from 0.75 in FY 2023-24. Interest Coverage Ratio stood at 1.33 in FY 2024-25, a recovery from 0.21 in the previous year, though finance costs rose to INR 907.28 Lakhs in H1 FY26 from INR 741.39 Lakhs in H1 FY25.

⚙️ Operational Drivers

Raw Materials

Key inputs include chemical intermediates for Anti-Malarial, Anti-Retroviral, and Anti-TB APIs. Specific chemical names are not listed, but raw material consumption is the primary cost driver for the API manufacturing process.

Capacity Expansion

Current operations are centered at the Vapi (Gujarat) facility. While specific MTPA figures are not provided, the company has historically expanded from Nimesulide into Anti-Malarial and Anti-Retroviral API production lines.

Raw Material Costs

Not disclosed as a specific percentage of revenue, but total expenses for H1 FY26 were INR 12,331.32 Lakhs, reflecting the high cost of chemical procurement for API synthesis.

Manufacturing Efficiency

Manufacturing efficiency is impacted by lower turnover; Inventory Turnover Ratio declined from 1.87 in FY24 to 1.28 in FY25, indicating slower movement of stock.

📈 Strategic Growth

Growth Strategy

Growth is targeted through the absorption of Mangalam Laboratories and Shri JB Pharma (merger hearing Dec 16, 2025), securing repeat international export orders (INR 15 Crore), and leveraging WHO/EDQM approvals to enter regulated global markets.

Products & Services

Active Pharmaceutical Ingredients (APIs) including Anti-Malarials (Artemether, Lumefantrine), Anti-Retrovirals, Anti-TB drugs, and Nimesulide.

Brand Portfolio

Mangalam Drugs & Organics Limited.

New Products/Services

The company has diversified from basic APIs into specialized Anti-Retroviral and Anti-Malarial products, with recent focus on repeat export orders contributing to revenue visibility.

Market Expansion

Expansion is focused on international markets, evidenced by the recent INR 15 Crore export order to be executed within a 2-4 month span.

Strategic Alliances

The company is undergoing a merger by absorption with Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited to achieve operational synergies.

🌍 External Factors

Industry Trends

The API industry is characterized by high entry barriers (2-3 years for new entrants) and stringent quality standards. There is a shift toward consolidated supply chains and a requirement for WHO/EDQM certifications.

Competitive Landscape

Competes with well-established large API players in the domestic and international markets, particularly in the Anti-Malarial and Anti-Retroviral segments.

Competitive Moat

The moat is built on regulatory approvals (WHO, EDQM) and the 2-3 year lead time required for competitors to establish manufacturing facilities and obtain necessary certifications.

Macro Economic Sensitivity

Highly sensitive to international healthcare funding policies and government regulations regarding pharmaceutical pricing and patent laws.

Consumer Behavior

Demand is driven by global health initiatives and the prevalence of infectious diseases like Malaria, HIV, and TB.

Geopolitical Risks

Changes in U.S. government fiscal policies, specifically the discontinuation of US-AID funding, pose a direct threat to the demand for the company's core API products.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Companies Act 2013, SEBI Listing Regulations, and international pharmaceutical standards set by WHO and EDQM.

Taxation Policy Impact

The company has recognized Deferred Tax Assets (DTA) on tax losses for H1 FY26 based on management's projections of future taxable profits.

Legal Contingencies

The company is awaiting a final hearing from the National Company Law Tribunal (NCLT) on December 16, 2025, regarding the merger with Mangalam Laboratories and Shri JB Pharma.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the financial impact of the loss of US-AID funding, which could lead to a sustained reduction in demand for the company's primary API products.